ATE348882T1 - Humanisierte monoklonale integrin antikörper - Google Patents

Humanisierte monoklonale integrin antikörper

Info

Publication number
ATE348882T1
ATE348882T1 AT99961810T AT99961810T ATE348882T1 AT E348882 T1 ATE348882 T1 AT E348882T1 AT 99961810 T AT99961810 T AT 99961810T AT 99961810 T AT99961810 T AT 99961810T AT E348882 T1 ATE348882 T1 AT E348882T1
Authority
AT
Austria
Prior art keywords
humanized monoclonal
antibodies
integrin antibodies
sub
receptors
Prior art date
Application number
AT99961810T
Other languages
English (en)
Inventor
Kyung O Johanson
Zdenka L Jonak
Alexander H Taylor
Stephen H Trulli
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of ATE348882T1 publication Critical patent/ATE348882T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT99961810T 1998-11-24 1999-11-24 Humanisierte monoklonale integrin antikörper ATE348882T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/199,149 US6160099A (en) 1998-11-24 1998-11-24 Anti-human αv β3 and αv β5 antibodies

Publications (1)

Publication Number Publication Date
ATE348882T1 true ATE348882T1 (de) 2007-01-15

Family

ID=22736426

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99961810T ATE348882T1 (de) 1998-11-24 1999-11-24 Humanisierte monoklonale integrin antikörper

Country Status (7)

Country Link
US (2) US6160099A (de)
EP (1) EP1135477B1 (de)
JP (1) JP2002530108A (de)
AT (1) ATE348882T1 (de)
DE (1) DE69934515T2 (de)
ES (1) ES2279646T3 (de)
WO (1) WO2000031248A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0968290B1 (de) * 1997-03-12 2004-12-15 SmithKline Beecham Corporation Anti-alphavbeta3 humanizierte monoklonale antikörper
US7387779B2 (en) 1998-06-17 2008-06-17 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
US6962974B1 (en) 1998-06-17 2005-11-08 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
US6759047B1 (en) 1998-06-17 2004-07-06 Beth Israel Deaconess Hospital Corp. Anti-angiogenic proteins and methods of use thereof
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
AU2001268545A1 (en) * 2000-06-21 2002-01-08 Alexion Pharmaceuticals, Inc. Libraries displaying human antibody fragments with hybrid complementarity determining regions
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US7288390B2 (en) * 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US20020147312A1 (en) * 2001-02-02 2002-10-10 O'keefe Theresa Hybrid antibodies and uses thereof
CA2439852A1 (en) * 2001-03-02 2002-09-12 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists
CA2478317A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate
WO2003075957A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
WO2003086458A1 (en) 2002-04-12 2003-10-23 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
WO2004066956A2 (en) * 2003-01-30 2004-08-12 Medimmune, Inc. Uses of integrin alphavbeta3 antagonists
JP4685764B2 (ja) * 2003-04-10 2011-05-18 アボット バイオセラピューティクス コーポレイション 変異誘発による抗体のＦｃＲｎ結合親和力又は血清半減期の改変
AU2004229501B2 (en) 2003-04-11 2011-08-18 Medimmune, Llc Recombinant IL-9 antibodies and uses thereof
WO2005037867A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
CA2585717A1 (en) 2004-10-27 2006-05-04 Medimmune Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
US8603483B2 (en) 2004-12-09 2013-12-10 Janssen Biotech, Inc. Anti-integrin immunoconjugates, methods and uses
EP2043603A4 (de) 2006-07-11 2010-10-27 Arubor Corp Prävention und therapie von rhinosinusitis mit proinflammatorischen zytokinhemmern
HUE048024T2 (hu) 2006-08-10 2020-05-28 Roy C Levitt Anakinra bronchiolitis obliterans szindróma kezelésében való alkalmazásra
US20090196913A1 (en) * 2007-05-11 2009-08-06 Ken Shi Kun Huang Anti-Alpha-V Immunoliposome Composition, Methods, and Uses
AU2011217848B8 (en) 2010-02-18 2015-09-24 The Regents Of The University Of California Integrin aVB8 neutralizing antibody
KR102010098B1 (ko) * 2011-08-17 2019-08-13 더 리전트 오브 더 유니버시티 오브 캘리포니아 인테그린 알파-v 베타-8에 결합하는 항체
US20130281355A1 (en) * 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
EP2740745A1 (de) 2012-12-05 2014-06-11 Momentive Specialty Chemicals Research Belgium S.A. Verfahren zur Herstellung von Polyvinylestherzusammensetzungen mit geringem Restmonomergehalt
KR101521224B1 (ko) 2012-12-20 2015-05-19 한양대학교 산학협력단 T 세포 특이적인 인간화 단일조각항체 전달체
WO2014144616A2 (en) * 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 5 antibodies and uses thereof
WO2015123654A1 (en) 2014-02-17 2015-08-20 The Cleveland Clinic Foundation Amine passivated nanoparticles for cancer treatment and imaging
EP3191519A1 (de) * 2014-09-12 2017-07-19 Biogen MA Inc. Humanisierte anti-alpha-v-beta-6-antikörper und verwendungen dafür
CA3172092A1 (en) * 2020-04-23 2021-10-28 David Cheresh Compositions and methods for treating cancer
CA3212408A1 (en) * 2021-03-09 2022-09-15 Sachdev S. Sidhu Antibodies against integrin heterodimers and uses thereof
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2807189A (en) * 1987-11-19 1989-07-05 Scripps Clinic And Research Foundation Monoclonal antibody against the rgd-directed adhesion receptor of endothelial cells
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9019812D0 (en) * 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
GB9207479D0 (en) * 1992-04-06 1992-05-20 Scotgen Ltd Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
NZ290008A (en) * 1994-06-29 1998-08-26 Smithkline Beecham Corp Vitronectin receptor antagonists, comprising a fibrinogen antagonist analogue linked to a heterocycle
ZA955391B (en) * 1994-06-29 1996-02-09 Smithkline Beecham Corp Vitronectin receptor antagonists
EP0719859B1 (de) * 1994-12-20 2003-07-02 MERCK PATENT GmbH Monoklonaler Antikörper gegen das Alpha-V-Integrin
ATE308981T1 (de) * 1995-08-14 2005-11-15 Scripps Research Inst Verfahren und mittel zur hemmung der durch alpha v beta 5 vermittelten angiogenese
EP0968290B1 (de) * 1997-03-12 2004-12-15 SmithKline Beecham Corporation Anti-alphavbeta3 humanizierte monoklonale antikörper
ES2230848T3 (es) * 1998-04-28 2005-05-01 Smithkline Beecham Corporation Anticuerpos monoclonales con inmunogenicidad reducida.

Also Published As

Publication number Publication date
US7087405B2 (en) 2006-08-08
EP1135477A4 (de) 2002-09-11
US6160099A (en) 2000-12-12
DE69934515T2 (de) 2007-09-27
EP1135477B1 (de) 2006-12-20
DE69934515D1 (de) 2007-02-01
JP2002530108A (ja) 2002-09-17
EP1135477A1 (de) 2001-09-26
WO2000031248A1 (en) 2000-06-02
ES2279646T3 (es) 2007-08-16
US20030004317A1 (en) 2003-01-02

Similar Documents

Publication Publication Date Title
ATE348882T1 (de) Humanisierte monoklonale integrin antikörper
BR0008688A (pt) Antagonistas de il-18 recombinantes utilizáveis no tratamento de distúrbios mediados por il-18
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
ATE394121T1 (de) Verwendung von antikörpern gegen das muc18- antigen
TWI263640B (en) Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
ATE364618T1 (de) Antikörper gegen das muc18-antigen
ATE316137T1 (de) Humanisierte antikörper gegen den epidermalen wachstumsfaktorrezeptor
AU2002359727A8 (en) Fused cyclic modulators of nuclear hormone receptor function
IN2012DN00313A (de)
GEP20084484B (en) Antibodies to insulin-like growth factor i receptor
IS6750A (is) Samrunnin heterósýklísk súkkínímíð efnasambönd oghliðstæður þeirra, stillar fyrir starfsemi kjarnahormónaviðtaka
IL181473A0 (en) Humanized anti-beta 7 antagonists and uses therefor
BR0315157A (pt) Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste
MY169308A (en) Treatment of tnf? related disorders
NZ324500A (en) Humanized antibodies to human gp39, compositions containing and therapeutic use thereof
AU2002364082A8 (en) Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
EA200301158A1 (ru) Антитела, блокирующие cripto, и их применения
DK0918774T3 (da) Androgenreceptormodulatorforbindelser og fremgangsmåder
ZA200508389B (en) Humanized antibodies to interferon alpha receptor-1(IFNAR-1)
DK1141286T3 (da) Kæde af cytokinreceptorer
ATE363531T1 (de) Claudin polypeptide
ATE235551T1 (de) Ligand (tie ligand-4) vom tie-2 rezeptor und dessen verwendungen
NZ515382A (en) OX2 receptor homologs
UA83988C2 (ru) Моноклональное антидвойное интегриновое антитело, которое специфически связывает человеческие интегрины альфа v бета 3 и альфа v бета 5, фармацевтическая композиция, которая его содержит, и их применение в терапии
TW200500465A (en) Novel humanized anti-vap-1 monoclonal antibody

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties